| 1 |
Hare AE, Makary MS. Locoregional Approaches in Cholangiocarcinoma Treatment. Cancers (Basel) 2022;14. [PMID: 36497334 DOI: 10.3390/cancers14235853] [Reference Citation Analysis]
|
| 2 |
Liu D, Heij LR, Czigany Z, Dahl E, Dulk MD, Lang SA, Ulmer TF, Neumann UP, Bednarsch J. The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma: a systematic review and meta-analysis. Sci Rep 2022;12:12691. [PMID: 35879385 DOI: 10.1038/s41598-022-16727-w] [Reference Citation Analysis]
|
| 3 |
Gilbert RWD, Lenet T, Cleary SP, Smoot R, Tzeng CD, Rocha FG, Martel G, Bertens KA. Does Caudate Resection Improve Outcomes of Patients Undergoing Curative Resection for Perihilar Cholangiocarcinoma? A Systematic Review and Meta-Analysis. Ann Surg Oncol 2022. [PMID: 35705775 DOI: 10.1245/s10434-022-11990-7] [Reference Citation Analysis]
|
| 4 |
Watanabe J, Miki A, Sakuma Y, Shimodaira K, Aoki Y, Meguro Y, Morishima K, Endo K, Sasanuma H, Lefor AK, Teratani T, Fukushima N, Kitayama J, Sata N. Preoperative Osteopenia Is Associated with Significantly Shorter Survival in Patients with Perihilar Cholangiocarcinoma. Cancers (Basel) 2022;14. [PMID: 35565342 DOI: 10.3390/cancers14092213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Liang L, Li C, Jia HD, Diao YK, Xing H, Pawlik TM, Lau WY, Shen F, Huang DS, Zhang CW, Yang T. Prognostic factors of resectable perihilar cholangiocarcinoma: a systematic review and meta-analysis of high-quality studies. Ther Adv Gastrointest Endosc 2021;14:2631774521993065. [PMID: 33629062 DOI: 10.1177/2631774521993065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Wang A, He Z, Cong P, Qu Y, Hu T, Cai Y, Sun B, Chen H, Fu W, Peng Y. Controlling Nutritional Status (CONUT) Score as a New Indicator of Prognosis in Patients With Hilar Cholangiocarcinoma Is Superior to NLR and PNI: A Single-Center Retrospective Study. Front Oncol 2020;10:593452. [PMID: 33505910 DOI: 10.3389/fonc.2020.593452] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 7 |
Suzuki Y, Sakamoto Y. Neoadjuvant Therapy and Conversion Surgery for Cholangiocarcinoma. Management of Pancreatic Cancer and Cholangiocarcinoma 2021. [DOI: 10.1007/978-981-16-2870-2_12] [Reference Citation Analysis]
|
| 8 |
Jingdong L, Yongfu X, Yang G, Jian X, Xujian H, Jianhua L, Wenxing Z, Renyi Q, Xinming Y, Shuguo Z, Xiao L, Bin P, Qifan Z, Dewei L, Zhao-Hui T. Minimally invasive surgery for hilar cholangiocarcinoma: a multicenter retrospective analysis of 158 patients. Surg Endosc 2020. [PMID: 33258033 DOI: 10.1007/s00464-020-08161-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 9 |
Nakahashi K, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Nagino M. How long should follow-up be continued after R0 resection of perihilar cholangiocarcinoma? Surgery 2020;168:617-24. [PMID: 32665142 DOI: 10.1016/j.surg.2020.04.068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 10 |
Birgin E, Rasbach E, Reissfelder C, Rahbari NN. A systematic review and meta-analysis of caudate lobectomy for treatment of hilar cholangiocarcinoma. Eur J Surg Oncol 2020;46:747-53. [PMID: 31987703 DOI: 10.1016/j.ejso.2020.01.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 11 |
Peng D, Lu J, Hu H, Li B, Ye X, Cheng N. Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma. J Gastrointest Surg 2020;24:330-40. [PMID: 30671792 DOI: 10.1007/s11605-018-04086-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 12 |
Bird NTE, Manu N, Quinn L, Needham A, Jones R, Fenwick S, Poston G, Palmer D, Malik H. Evaluation of the utility of prognostic models for patients with resected hilar cholangiocarcinoma. HPB (Oxford) 2019;21:1376-84. [PMID: 31078423 DOI: 10.1016/j.hpb.2019.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 13 |
Kovalenko YA, Zharikov YO, Kukeev IA, Vishnevsky VA, Chzhao AV. [Predictors of outcomes in surgery for hilar cholangiocarcinoma]. Khirurgiia (Mosk) 2018;:5-11. [PMID: 30531729 DOI: 10.17116/hirurgia20181015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 14 |
Hu HJ, Jin YW, Shrestha A, Ma WJ, Wang JK, Liu F, Zhu YY, Zhou RX, Regmi P, Cheng NS, Li FY. Predictive factors of early recurrence after R0 resection of hilar cholangiocarcinoma: A single institution experience in China. Cancer Med 2019;8:1567-75. [PMID: 30868740 DOI: 10.1002/cam4.2052] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 15 |
Hu HJ, Jin YW, Zhou RX, Ma WJ, Yang Q, Wang JK, Liu F, Cheng NS, Li FY. Clinical Value of Inflammation-Based Prognostic Scores to Predict the Resectability of Hyperbilirubinemia Patients with Potentially Resectable Hilar Cholangiocarcinoma. J Gastrointest Surg 2019;23:510-7. [PMID: 30076591 DOI: 10.1007/s11605-018-3892-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 16 |
Sallinen V, Sirén J, Mäkisalo H, Lehtimäki TE, Lantto E, Kokkola A, Nordin A. Differences in Prognostic Factors and Recurrence Patterns After Curative-Intent Resection of Perihilar and Distal Cholangiocarcinomas. Scand J Surg 2020;109:219-27. [PMID: 30791825 DOI: 10.1177/1457496919832150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 17 |
Ji GW, Zhang YD, Wang K, Zhang H, Shao ZC, Jiang WJ, Li XC, Wang XH. Short- and long-term outcomes of middle hepatic vein-oriented hepatectomy for advanced perihilar cholangiocarcinoma. J Surg Oncol 2018;118:446-54. [PMID: 30098303 DOI: 10.1002/jso.25181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 18 |
Blaga MM, Brasoveanu V, Stroescu C, Ionescu M, Popescu I, Dumitrascu T. Pattern of the First Recurrence Has No Impact on Long-Term Survival after Curative Intent Surgery for Perihilar Cholangiocarcinomas. Gastroenterol Res Pract 2018;2018:2546257. [PMID: 30158963 DOI: 10.1155/2018/2546257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 19 |
Wang Y, Fu W, Tang Z, Meng W, Zhou W, Li X. Effect of preoperative cholangitis on prognosis of patients with hilar cholangiocarcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12025. [PMID: 30142851 DOI: 10.1097/MD.0000000000012025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 20 |
Yu Z, Zhu J, Jiang H, He C, Xiao Z, Wang J, Xu J. Surgical Resection and Prognostic Analysis of 142 Cases of Hilar Cholangiocarcinoma. Indian J Surg 2018;80:309-17. [PMID: 32288384 DOI: 10.1007/s12262-016-1581-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 21 |
Tang Z, Yang Y, Zhao Z, Wei K, Meng W, Li X. The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11999. [PMID: 30142840 DOI: 10.1097/MD.0000000000011999] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 22 |
Bird NTE, McKenna A, Dodd J, Poston G, Jones R, Malik H. Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. Br J Surg. 2018;105:1408-1416. [PMID: 29999515 DOI: 10.1002/bjs.10921] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 23 |
Burt AD, Alves V, Bedossa P, Clouston A, Guido M, Hübscher S, Kakar S, Ng I, Park YN, Reeves H, Wyatt J, Yeh MM, Ellis DW. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2018;73:369-85. [DOI: 10.1111/his.13520] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 24 |
Pinotti E, Sandini M, Famularo S, Tamini N, Romano F, Gianotti L. Resection of the caudate lobe for the treatment of hilar cholangiocarcinoma. Minerva Chir 2019;74:348-58. [PMID: 29658674 DOI: 10.23736/S0026-4733.18.07498-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 25 |
Wang JK, Hu HJ, Shrestha A, Ma WJ, Yang Q, Liu F, Cheng NS, Li FY. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma? Oncotarget 2017;8:45335-44. [PMID: 28484084 DOI: 10.18632/oncotarget.17336] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 26 |
Tang H, Lu W, Li B, Li C, Xu Y, Dong J. Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis. Oncotarget 2017;8:36857-68. [PMID: 28415734 DOI: 10.18632/oncotarget.16143] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 27 |
Cho KM, Park H, Oh DY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. Oncotarget 2017;8:2329-41. [PMID: 27911876 DOI: 10.18632/oncotarget.13731] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 28 |
Xu ZG, Ye CJ, Liu LX, Wu G, Zhao ZX, Wang YZ, Shi BQ, Wang YH. The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis. Biomark Med. 2018;12:189-199. [PMID: 29327595 DOI: 10.2217/bmm-2017-0307] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 29 |
Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery 2018;163:732-8. [PMID: 29336813 DOI: 10.1016/j.surg.2017.08.011] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 11.2] [Reference Citation Analysis]
|
| 30 |
Capobianco I, Rolinger J, Nadalin S. Resection for Klatskin tumors: technical complexities and results. Transl Gastroenterol Hepatol 2018;3:69. [PMID: 30363698 DOI: 10.21037/tgh.2018.09.01] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 31 |
Min GT, Li YM, Yao N, Wang J, Wang HP, Chen W. The pretreatment neutrophil-lymphocyte ratio may predict prognosis of patients with liver cancer: A systematic review and meta-analysis. Clin Transplant. 2018;32. [PMID: 29112283 DOI: 10.1111/ctr.13151] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 32 |
Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis. Sci Rep. 2017;7:16717. [PMID: 29196718 DOI: 10.1038/s41598-017-16955-5] [Cited by in Crossref: 156] [Cited by in F6Publishing: 171] [Article Influence: 26.0] [Reference Citation Analysis]
|
| 33 |
Hu HJ, Zhou RX, Shrestha A, Tan YQ, Ma WJ, Yang Q, Lu J, Wang JK, Zhou Y, Li FY. Relationship of tumor size with pathological and prognostic factors for hilar cholangiocarcinoma. Oncotarget 2017;8:105011-9. [PMID: 29285229 DOI: 10.18632/oncotarget.22054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 34 |
Schoellhammer HF, Fong Y, Singh G. Extrahepatic bile duct tumors. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set 2017. [DOI: 10.1016/b978-0-323-34062-5.00051-0] [Reference Citation Analysis]
|
| 35 |
Tan DW, Fu Y, Su Q, Guan MJ, Kong P, Wang SQ, Wang HL. Prognostic Significance of Neutrophil to Lymphocyte Ratio in Oncologic Outcomes of Cholangiocarcinoma: A Meta-analysis. Sci Rep. 2016;6:33789. [PMID: 27694951 DOI: 10.1038/srep33789] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 36 |
Abd ElWahab M, El Nakeeb A, El Hanafy E, Sultan AM, Elghawalby A, Askr W, Ali M, Abd El Gawad M, Salah T. Predictors of long term survival after hepatic resection for hilar cholangiocarcinoma: A retrospective study of 5-year survivors. World J Gastrointest Surg 2016; 8(6): 436-443 [PMID: 27358676 DOI: 10.4240/wjgs.v8.i6.436] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 37 |
Bhardwaj N, Garcea G, Dennison AR, Maddern GJ. The Surgical Management of Klatskin Tumours: Has Anything Changed in the Last Decade? World J Surg 2015;39:2748-56. [PMID: 26133907 DOI: 10.1007/s00268-015-3125-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 38 |
Hu HJ, Mao H, Tan YQ, Shrestha A, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. Springerplus. 2016;5:551. [PMID: 27190750 DOI: 10.1186/s40064-016-2181-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 39 |
Saito H, Noji T, Okamura K, Tsuchikawa T, Shichinohe T, Hirano S. A new prognostic scoring system using factors available preoperatively to predict survival after operative resection of perihilar cholangiocarcinoma. Surgery 2016;159:842-51. [DOI: 10.1016/j.surg.2015.10.027] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 40 |
Hu HJ, Mao H, Shrestha A, Tan YQ, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol 2016; 22(8): 2601-2610 [PMID: 26937148 DOI: 10.3748/wjg.v22.i8.2601] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 41 |
Sirohi B, Rastogi S, Singh A, Sheth V, Dawood S, Talole S, Ramadwar M, Kulkarni S, Shrikhande SV. Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer. Future Oncol 2015;11:1191-200. [PMID: 25832876 DOI: 10.2217/fon.14.295] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 42 |
Okuno M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Evaluation of inflammation-based prognostic scores in patients undergoing hepatobiliary resection for perihilar cholangiocarcinoma. J Gastroenterol 2016;51:153-61. [PMID: 26187429 DOI: 10.1007/s00535-015-1103-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 43 |
Lee BS, Lee SH, Son JH, Jang DK, Chung KH, Lee YS, Paik WH, Ryu JK, Kim YT. Neutrophil-lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy. Cancer Immunol Immunother 2016;65:141-50. [PMID: 26728479 DOI: 10.1007/s00262-015-1780-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 44 |
Akamatsu N, Sugawara Y, Kokudo N. The Assessment of Ductal Margin in Curative-Intent Surgery for Perihilar Cholangiocarcinoma. Difficult Decisions in Surgery: An Evidence-Based Approach 2016. [DOI: 10.1007/978-3-319-27365-5_31] [Reference Citation Analysis]
|
| 45 |
Hammad AY, Berger NG, Gamblin TC. Point-of-Care Clinical Guide: Cholangiocarcinoma. Pancreas and Biliary Disease 2016. [DOI: 10.1007/978-3-319-28089-9_13] [Reference Citation Analysis]
|
| 46 |
Groot Koerkamp B, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch OR, Coelen RJ, D'Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, Jarnagin WR, van Gulik TM. Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. J Am Coll Surg. 2015;221:1041-1049. [PMID: 26454735 DOI: 10.1016/j.jamcollsurg.2015.09.005] [Cited by in Crossref: 92] [Cited by in F6Publishing: 100] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 47 |
Grenader T, Nash S, Plotkin Y, Furuse J, Mizuno N, Okusaka T, Wasan H, Valle J, Bridgewater J. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. Annals of Oncology 2015;26:1910-6. [DOI: 10.1093/annonc/mdv253] [Cited by in Crossref: 36] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 48 |
Kainuma O, Miura F, Furukawa D, Yamamoto H, Cho A, Sano K, Nakagohri T, Asano T. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer. J Hepatobiliary Pancreat Sci 2015;22:789-94. [PMID: 26234468 DOI: 10.1002/jhbp.283] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 49 |
Dumitrascu T, Brasoveanu V, Stroescu C, Ionescu M, Popescu I. Major hepatectomies for perihilar cholangiocarcinoma: Predictors for clinically relevant postoperative complications using the International Study Group of Liver Surgery definitions. Asian J Surg. 2016;39:81-89. [PMID: 26103932 DOI: 10.1016/j.asjsur.2015.04.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 50 |
Xiang S, Lau WY, Chen XP. Hilar cholangiocarcinoma: controversies on the extent of surgical resection aiming at cure. Int J Colorectal Dis 2015;30:159-71. [PMID: 25376337 DOI: 10.1007/s00384-014-2063-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 51 |
Weiss MJ, Cosgrove D, Herman JM, Rastegar N, Kamel I, Pawlik TM. Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbecks Arch Surg. 2014;399:679-692. [PMID: 24962146 DOI: 10.1007/s00423-014-1219-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 52 |
Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3:18-34. [PMID: 24696835 DOI: 10.3978/j.issn.2304-3881.2014.02.05] [Cited by in F6Publishing: 59] [Reference Citation Analysis]
|
| 53 |
Yanagisawa N, Hana K, Nakada N, Ichinoe M, Koizumi W, Endou H, Okayasu I, Murakumo Y. High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas. Cancer Med 2014;3:1246-55. [PMID: 24890221 DOI: 10.1002/cam4.272] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 54 |
Templeton AJ, Mcnamara MG, Šeruga B, Vera-badillo FE, Aneja P, Ocaña A, Leibowitz-amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute 2014;106. [DOI: 10.1093/jnci/dju124] [Cited by in Crossref: 1645] [Cited by in F6Publishing: 1711] [Article Influence: 182.8] [Reference Citation Analysis]
|
| 55 |
Popescu I, Dumitrascu T. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg 2014;399:693-705. [PMID: 24841192 DOI: 10.1007/s00423-014-1210-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 56 |
Xue TC, Zhang L, Xie XY, Ge NL, Li LX, Zhang BH, Ye SL, Ren ZG. Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis. PLoS One 2014;9:e96072. [PMID: 24788770 DOI: 10.1371/journal.pone.0096072] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 57 |
Bugada D, Allegri M, Lavand'homme P, De Kock M, Fanelli G. Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients. Biomed Res Int 2014;2014:142425. [PMID: 24877056 DOI: 10.1155/2014/142425] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 58 |
McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, Min T, Amir E, Knox JJ. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014;50:1581-1589. [PMID: 24630393 DOI: 10.1016/j.ejca.2014.02.015] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 59 |
Iwaku A, Kinoshita A, Onoda H, Fushiya N, Nishino H, Matsushima M, Tajiri H. The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection. Med Oncol 2014;31:787. [PMID: 24310810 DOI: 10.1007/s12032-013-0787-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
